Miller Eric Alejandro 4
4 · ACADIA PHARMACEUTICALS INC · Filed Sep 11, 2019
Insider Transaction Report
Form 4
Miller Eric Alejandro
Controller & PAO
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2019-09-09−3,900→ 0 totalExercise: $32.28Exp: 2025-01-25→ Common Stock (3,900 underlying) - Exercise/Conversion
Common Stock
2019-09-09$36.54/sh+4,439$162,201→ 26,547 total - Sale
Common Stock
2019-09-09$39.49/sh−28,467$1,124,162→ 4,645 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-09-09−4,593→ 4,594 totalExercise: $35.80Exp: 2027-09-06→ Common Stock (4,593 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2019-09-09−1,972→ 3,598 totalExercise: $16.50Exp: 2028-04-06→ Common Stock (1,972 underlying) - Exercise/Conversion
Common Stock
2019-09-09$32.28/sh+3,900$125,892→ 16,045 total - Exercise/Conversion
Common Stock
2019-09-09$16.50/sh+1,972$32,538→ 33,112 total - Sale
Common Stock
2019-09-11$41.18/sh−4,645$191,281→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-09-09−4,439→ 2,911 totalExercise: $36.54Exp: 2027-03-07→ Common Stock (4,439 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2019-09-09−6,063→ 552 totalExercise: $29.24Exp: 2026-01-05→ Common Stock (6,063 underlying) - Exercise/Conversion
Common Stock
2019-09-09$29.24/sh+6,063$177,282→ 22,108 total - Exercise/Conversion
Common Stock
2019-09-09$20.65/sh+7,500$154,875→ 12,145 total - Exercise/Conversion
Common Stock
2019-09-09$35.80/sh+4,593$164,429→ 31,140 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-09-09−7,500→ 0 totalExercise: $20.65Exp: 2024-05-29→ Common Stock (7,500 underlying)
Footnotes (8)
- [F1]Includes 860 shares of the Issuer's common stock acquired by the reporting person on November 15, 2018 and 573 shares of the Issuer's common stock acquired by the reporting person on May 15, 2019 pursuant to an employee stock purchase program.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.49 to $39.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.1401 to $41.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The option is fully vested and exercisable.
- [F5]25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2017, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- [F6]25% of the shares subject to the Stock Option vested and became exercisable on March 8, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- [F7]25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- [F8]25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.